315 related articles for article (PubMed ID: 32085572)
1. Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.
Majera D; Skrott Z; Chroma K; Merchut-Maya JM; Mistrik M; Bartek J
Cells; 2020 Feb; 9(2):. PubMed ID: 32085572
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel dithiocarbamate-copper complexes targeting p97/NPL4 pathway in cancer cells.
Loffelmann M; Škrott Z; Majera D; Štarha P; Kryštof V; Mistrík M
Eur J Med Chem; 2023 Dec; 261():115790. PubMed ID: 37690264
[TBL] [Abstract][Full Text] [Related]
3. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.
Skrott Z; Mistrik M; Andersen KK; Friis S; Majera D; Gursky J; Ozdian T; Bartkova J; Turi Z; Moudry P; Kraus M; Michalova M; Vaclavkova J; Dzubak P; Vrobel I; Pouckova P; Sedlacek J; Miklovicova A; Kutt A; Li J; Mattova J; Driessen C; Dou QP; Olsen J; Hajduch M; Cvek B; Deshaies RJ; Bartek J
Nature; 2017 Dec; 552(7684):194-199. PubMed ID: 29211715
[TBL] [Abstract][Full Text] [Related]
4. Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET.
Kanellis DC; Zisi A; Skrott Z; Lemmens B; Espinoza JA; Kosar M; Björkman A; Li X; Arampatzis S; Bartkova J; Andújar-Sánchez M; Fernandez-Capetillo O; Mistrik M; Lindström MS; Bartek J
Cell Death Differ; 2023 Jul; 30(7):1666-1678. PubMed ID: 37142656
[TBL] [Abstract][Full Text] [Related]
5. ATRIP Deacetylation by SIRT2 Drives ATR Checkpoint Activation by Promoting Binding to RPA-ssDNA.
Zhang H; Head PE; Daddacha W; Park SH; Li X; Pan Y; Madden MZ; Duong DM; Xie M; Yu B; Warren MD; Liu EA; Dhere VR; Li C; Pradilla I; Torres MA; Wang Y; Dynan WS; Doetsch PW; Deng X; Seyfried NT; Gius D; Yu DS
Cell Rep; 2016 Feb; 14(6):1435-1447. PubMed ID: 26854234
[TBL] [Abstract][Full Text] [Related]
6. Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase.
Skrott Z; Majera D; Gursky J; Buchtova T; Hajduch M; Mistrik M; Bartek J
Oncogene; 2019 Oct; 38(40):6711-6722. PubMed ID: 31391554
[TBL] [Abstract][Full Text] [Related]
7. Seesaw conformations of Npl4 in the human p97 complex and the inhibitory mechanism of a disulfiram derivative.
Pan M; Zheng Q; Yu Y; Ai H; Xie Y; Zeng X; Wang C; Liu L; Zhao M
Nat Commun; 2021 Jan; 12(1):121. PubMed ID: 33402676
[TBL] [Abstract][Full Text] [Related]
8. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
10. DNA-PKcs is required to maintain stability of Chk1 and Claspin for optimal replication stress response.
Lin YF; Shih HY; Shang Z; Matsunaga S; Chen BP
Nucleic Acids Res; 2014 Apr; 42(7):4463-73. PubMed ID: 24500207
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer.
Liu K; Graves JD; Lin FT; Lin WC
J Biol Chem; 2021; 296():100382. PubMed ID: 33556369
[TBL] [Abstract][Full Text] [Related]
12. Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Majera D; Skrott Z; Bouchal J; Bartkova J; Simkova D; Gachechiladze M; Steigerova J; Kurfurstova D; Gursky J; Korinkova G; Cwiertka K; Hodny Z; Mistrik M; Bartek J
Prostate; 2019 Mar; 79(4):352-362. PubMed ID: 30499118
[TBL] [Abstract][Full Text] [Related]
13. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
14. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
15. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
[TBL] [Abstract][Full Text] [Related]
16. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
[TBL] [Abstract][Full Text] [Related]
17. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
18. ZFP161 regulates replication fork stability and maintenance of genomic stability by recruiting the ATR/ATRIP complex.
Kim W; Zhao F; Wu R; Qin S; Nowsheen S; Huang J; Zhou Q; Chen Y; Deng M; Guo G; Luo K; Lou Z; Yuan J
Nat Commun; 2019 Nov; 10(1):5304. PubMed ID: 31757956
[TBL] [Abstract][Full Text] [Related]
19. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
Edwards TG; Bloom DC; Fisher C
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
[TBL] [Abstract][Full Text] [Related]
20. The SUMO (Small Ubiquitin-like Modifier) Ligase PIAS3 Primes ATR for Checkpoint Activation.
Wu CS; Zou L
J Biol Chem; 2016 Jan; 291(1):279-90. PubMed ID: 26565033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
